TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. AU - Cowey, C. AU - Lao, C. PY - 2015 DA - 2015// TI - Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Weber, J. S. AU - D’Angelo, S. P. AU - Minor, D. AU - Hodi, F. S. AU - Gutzmer, R. AU - Neyns, B. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Topalian, S. L. AU - Sznol, M. AU - McDermott, D. F. AU - Kluger, H. M. AU - Carvajal, R. D. AU - Sharfman, W. H. PY - 2014 DA - 2014// TI - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0105 DO - 10.1200/JCO.2013.53.0105 ID - Topalian2014 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Chiarion-Sileni, V. AU - Grob, J. -. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2015 DA - 2015// TI - Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70122-1 DO - 10.1016/S1470-2045(15)70122-1 ID - Eggermont2015 ER - TY - JOUR AU - Lebbe, C. AU - Weber, J. S. AU - Maio, M. AU - Neyns, B. AU - Harmankaya, K. AU - Hamid, O. PY - 2014 DA - 2014// TI - Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies JO - Ann Oncol Off J Eur Soc Med Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu441 DO - 10.1093/annonc/mdu441 ID - Lebbe2014 ER - TY - JOUR AU - Wolchok, J. D. AU - Kluger, H. AU - Callahan, M. K. AU - Postow, M. A. AU - Rizvi, N. A. AU - Lesokhin, A. M. PY - 2013 DA - 2013// TI - Nivolumab plus ipilimumab in advanced melanoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1302369 DO - 10.1056/NEJMoa1302369 ID - Wolchok2013 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Haanen, J. B. A. G. AU - Carbonnel, F. AU - Robert, C. AU - Kerr, K. M. AU - Peters, S. AU - Larkin, J. PY - 2017 DA - 2017// TI - Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx225 DO - 10.1093/annonc/mdx225 ID - Haanen2017 ER - TY - JOUR AU - Liao, B. AU - Shroff, S. AU - Kamiya-Matsuoka, C. AU - Tummala, S. PY - 2014 DA - 2014// TI - Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma JO - Neuro-Oncology VL - 16 UR - https://doi.org/10.1093/neuonc/nou001 DO - 10.1093/neuonc/nou001 ID - Liao2014 ER - TY - JOUR AU - Perrinjaquet, C. AU - Desbaillets, N. AU - Hottinger, A. F. PY - 2019 DA - 2019// TI - Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy JO - Curr Opin Neurol VL - 32 UR - https://doi.org/10.1097/WCO.0000000000000686 DO - 10.1097/WCO.0000000000000686 ID - Perrinjaquet2019 ER - TY - JOUR AU - Larkin, J. AU - Chmielowski, B. AU - Lao, C. D. AU - Hodi, F. S. AU - Sharfman, W. AU - Weber, J. PY - 2017 DA - 2017// TI - Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis JO - Oncologist. VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0487 DO - 10.1634/theoncologist.2016-0487 ID - Larkin2017 ER - TY - JOUR AU - Hottinger, A. F. PY - 2016 DA - 2016// TI - Neurologic complications of immune checkpoint inhibitors JO - Curr Opin Neurol VL - 29 UR - https://doi.org/10.1097/WCO.0000000000000391 DO - 10.1097/WCO.0000000000000391 ID - Hottinger2016 ER - TY - JOUR AU - Maurice, C. AU - Schneider, R. AU - Kiehl, T. -. R. AU - Bavi, P. AU - Roehrl, M. H. A. AU - Mason, W. P. PY - 2015 DA - 2015// TI - Subacute CNS demyelination after treatment with Nivolumab for melanoma JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0141 DO - 10.1158/2326-6066.CIR-15-0141 ID - Maurice2015 ER - TY - JOUR AU - Cao, Y. AU - Nylander, A. AU - Ramanan, S. AU - Goods, B. A. AU - Ponath, G. AU - Zabad, R. PY - 2016 DA - 2016// TI - CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment JO - Neurology. VL - 86 UR - https://doi.org/10.1212/WNL.0000000000002594 DO - 10.1212/WNL.0000000000002594 ID - Cao2016 ER - TY - JOUR AU - Duraes, J. AU - Coutinho, I. AU - Mariano, A. AU - Geraldo, A. AU - Macario, M. C. PY - 2019 DA - 2019// TI - Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma JO - Mult Scler VL - 25 UR - https://doi.org/10.1177/1352458518803724 DO - 10.1177/1352458518803724 ID - Duraes2019 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Chiarion-Sileni, V. AU - Grob, J. -. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2016 DA - 2016// TI - Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611299 DO - 10.1056/NEJMoa1611299 ID - Eggermont2016 ER - TY - JOUR AU - Cuzzubbo, S. AU - Javeri, F. AU - Tissier, M. AU - Roumi, A. AU - Barlog, C. AU - Doridam, J. PY - 2017 DA - 2017// TI - Neurological adverse events associated with immune checkpoint inhibitors: review of the literature JO - Eur J Cancer VL - 73 UR - https://doi.org/10.1016/j.ejca.2016.12.001 DO - 10.1016/j.ejca.2016.12.001 ID - Cuzzubbo2017 ER - TY - JOUR AU - Johnson, D. B. AU - Manouchehri, A. AU - Haugh, A. M. AU - Quach, H. T. AU - Balko, J. M. AU - Lebrun-Vignes, B. PY - 2019 DA - 2019// TI - Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0617-x DO - 10.1186/s40425-019-0617-x ID - Johnson2019 ER - TY - JOUR AU - Malani, R. AU - Haggiagi, A. AU - Holder, J. AU - Shames, Y. AU - Briggs, S. AU - Callahan, M. PY - 2018 DA - 2018// TI - Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis (N6.001) JO - Neurology VL - 90 ID - Malani2018 ER - TY - JOUR AU - Takizawa, S. AU - Kaneyama, T. AU - Tsugane, S. AU - Takeichi, N. AU - Yanagisawa, S. AU - Ichikawa, M. PY - 2014 DA - 2014// TI - Role of the programmed Death-1 (PD-1) pathway in regulation of Theiler’s murine encephalomyelitis virus-induced demyelinating disease JO - J Neuroimmunol VL - 274 UR - https://doi.org/10.1016/j.jneuroim.2014.06.018 DO - 10.1016/j.jneuroim.2014.06.018 ID - Takizawa2014 ER - TY - JOUR AU - Salama, A. D. AU - Chitnis, T. AU - Imitola, J. AU - Ansari, M. J. I. AU - Akiba, H. AU - Tushima, F. PY - 2003 DA - 2003// TI - Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis JO - J Exp Med VL - 198 UR - https://doi.org/10.1084/jem.20022119 DO - 10.1084/jem.20022119 ID - Salama2003 ER - TY - JOUR AU - Kroner, A. AU - Mehling, M. AU - Hemmer, B. AU - Rieckmann, P. AU - Toyka, K. V. AU - Maurer, M. PY - 2005 DA - 2005// TI - A PD-1 polymorphism is associated with disease progression in multiple sclerosis JO - Ann Neurol VL - 58 UR - https://doi.org/10.1002/ana.20514 DO - 10.1002/ana.20514 ID - Kroner2005 ER -